Detail Information of Exogenous Modulation
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0008 Transporter Info | ||||
| Gene Name | SLCO1B1 | ||||
| Transporter Name | Organic anion transporting polypeptide 1B1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
|---|---|---|---|---|---|
Cyanotoxin |
|||||
cyanoginosin LR |
6 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dehydroepiandrosterone Sulfate inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cyanoginosin LR | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [113] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cyanoginosin LR | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [114] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Taurocholic Acid inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
microcystin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased susceptibility to microcystin analog | [114] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
microcystin-LF |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased susceptibility to microcystin-LF | [114] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Nanoparticle |
|||||
perfluoro-n-nonanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluoro-n-nonanoic acid results in decreased expression of SLCO1B1 mRNA | [136] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Rifampicin |
11 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifampicin inhibits the transportation of Atorvastatin by SLCO1B1 (IC50 = 3.25 microM; Ki = 3.08 microM) | [1] | |||
Affected Drug/Substrate |
Atorvastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Rifampicin inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 3.2 microM) | [2] | |||
Affected Drug/Substrate |
Bosentan | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1B1 (Ki = 17 microM) | [3] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OATP1B1 | ||||
DT Modulation4 |
Rifampicin inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 120 microM) | [4] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
DT Modulation5 |
Rifampicin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.8 microM; Ki = 1.6 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation6 |
Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.94 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation7 |
Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.5 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation8 |
Rifampicin inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.48 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation9 |
Rifampicin inhibits the transportation of Sulfobromophthalein by SLCO1B1 (Ki = 17 microM) | [3] | |||
Affected Drug/Substrate |
Sulfobromophthalein | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OATP1B1 | ||||
DT Modulation10 |
Rifampicin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B1 | [13] | |||
Affected Drug/Substrate |
Estradiol 17b-D-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation11 |
Rifampicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cyclosporine |
18 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cyclosporine inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 0.3 microM) | [2] | |||
Affected Drug/Substrate |
Bosentan | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Cyclosporine inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 3.5 microM) | [4] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
DT Modulation3 |
Cyclosporine inhibits the transportation of Cerivastatin by SLCO1B1 (Ki = 0.238 microM) | [5] | |||
Affected Drug/Substrate |
Cerivastatin | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
DT Modulation4 |
Cyclosporine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.37 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation5 |
Cyclosporine inhibits the transportation of Phalloidin by SLCO1B1 (Ki = 0.2 microM) | [9] | |||
Affected Drug/Substrate |
Phalloidin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation6 |
Cyclosporine inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.24 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation7 |
Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 2.2 microM) | [11] | |||
Affected Drug/Substrate |
Rosuvastatin | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OATP1B1 | ||||
DT Modulation8 |
Cyclosporine inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 0.31 microM) | [12] | |||
Affected Drug/Substrate |
Rosuvastatin | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation9 |
Cyclosporine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation10 |
Cyclosporine inhibits the transportation of Pitavastatin calcium by SLCO1B1 | [15] | |||
Affected Drug/Substrate |
Pitavastatin calcium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation11 |
Cyclosporine inhibits the activity of SLCO1B1 | [11], [16] | |||
Paclitaxel |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Paclitaxel inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 50 microM) | [4] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
DT Modulation2 |
Paclitaxel inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.03 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Paclitaxel inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Paclitaxel inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
DT Modulation5 |
Paclitaxel inhibits the activity of SLCO1B1 | [19] | |||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Lovastatin |
7 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lovastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 6.1 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Lovastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 12.7 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Lovastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Lovastatin inhibits the transportation of Pravastatin by SLCO1B1 | [18] | |||
Affected Drug/Substrate |
Pravastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation5 |
Lovastatin inhibits the transportation of Sodium taurocholate by SLCO1B1 | [18] | |||
Affected Drug/Substrate |
Sodium taurocholate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Rifamycin SV |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifamycin SV inhibits the transportation of Bromsulphthalein by SLCO1B1 (Ki = 2 microM) | [3] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Oocytes-OATP1B1 | ||||
DT Modulation2 |
Rifamycin SV inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.17 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation3 |
Rifamycin SV inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Rifamycin SV inhibits the activity of SLCO1B1 | [23] | |||
Ritonavir |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ritonavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.6 microM; Ki = 1.4 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Ritonavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.71 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation3 |
Ritonavir inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.78 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Ritonavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Saquinavir |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Saquinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 2.1 microM; Ki = 1.8 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Saquinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.23 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation3 |
Saquinavir inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 1.59 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Saquinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Estradiol |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 3.9 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 3.3 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Estradiol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation4 |
Estradiol inhibits the transportation of Estrone sulfate by SLCO1B1 | [21] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Indinavir |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Indinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 12.2 microM; Ki = 10.8 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Indinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 5.84 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation3 |
Indinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Lopinavir |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lopinavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 0.5 microM; Ki = 0.5 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Lopinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation3 |
Lopinavir inhibits the activity of SLCO1B1 | [6] | |||
Gemfibrozil |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Gemfibrozil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 12.5 microM) | [24] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Gemfibrozil inhibits the transportation of Rosuvastatin by SLCO1B1 (IC50 = 25 microM) | [12] | |||
Affected Drug/Substrate |
Rosuvastatin | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation3 |
Gemfibrozil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Clotrimazole |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Clotrimazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 9 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Clotrimazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 7.6 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Clotrimazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Mifepristone |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 3.3 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 2.2 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation3 |
Mifepristone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sildenafil |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sildenafil inhibits the transportation of Bosentan by SLCO1B1 (IC50 = 1.5 microM) | [2] | |||
Affected Drug/Substrate |
Bosentan | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Sildenafil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Repaglinide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Repaglinide inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 2.2 microM) | [25] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Repaglinide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Amprenavir |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amprenavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 14.4 microM; Ki = 12.8 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Amprenavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Atazanavir |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 1.7 microM; Ki = 1.5 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Atazanavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Digoxin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Digoxin inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 7.9 microM; Ki = 7 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Digoxin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nelfinavir |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nelfinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.93 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation2 |
Nelfinavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Troglitazone |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Troglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 1.2 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Troglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 1 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Bezafibrate |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bezafibrate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 45.2 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Bezafibrate inhibits the activity of SLCO1B1 | [41] | |||
Chenodeoxycholic acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chenodeoxycholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 3.4 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Chenodeoxycholic acid inhibits the activity of SLCO1B1 | [39] | |||
Cholic Acid |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 25 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Cholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fenofibrate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fenofibrate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 105.2 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Fenofibrate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Pravastatin |
11 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pravastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 21.8 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Pravastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Simvastatin |
10 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Simvastatin inhibits the transportation of estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 9.7 +/- 0.2 microM) | [27] | |||
Affected Drug/Substrate |
estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Simvastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fexofenadine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fexofenadine inhibits the transportation of Estrone sulfate by SLCO1B1 (Ki = 257 microM) | [28] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Fexofenadine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tacrolimus |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tacrolimus inhibits the transportation of Phalloidin by SLCO1B1 (IC50 = 3.7 microM) | [9] | |||
Affected Drug/Substrate |
Phalloidin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Tacrolimus inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.61 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Glyburide |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glibenclamide inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.75 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Glibenclamide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Telmisartan |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Telmisartan inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 0.44 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Telmisartan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Valsartan |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valsartan inhibits the transportation of Pitavastatin by SLCO1B1 (Ki = 8.96 microM) | [10] | |||
Affected Drug/Substrate |
Pitavastatin | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Valsartan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Indocyanine green |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Indocyanine green inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [32] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Indocyanine green inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Atorvastatin |
16 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atorvastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Atorvastatin induces the activity of SLCO1B1 | [37] | |||
DT Modulation3 |
Apigenin inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Atorvastatin inhibits the reaction SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Atorvastatin results in decreased activity of SLCO1B1 protein | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
glimepiride inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glyburide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
kaempferol inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Nateglinide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Pioglitazone inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
Quercetin inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
repaglinide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation13 |
Rosiglitazone inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation14 |
SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation15 |
SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation16 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [102] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Doxorubicin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Doxorubicin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Doxorubicin inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Ibuprofen |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ibuprofen inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Ibuprofen induces the activity of SLCO1B1 | [40] | |||
Irinotecan |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Irinotecan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Irinotecan inhibits the transportation of Estrone sulfate by SLCO1B1 | [33] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ketoconazole |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ketoconazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Ketoconazole inhibits the activity of SLCO1B1 | [38] | |||
Mitoxantrone |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Mitoxantrone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Mitoxantrone inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Phenobarbital |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenobarbital inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Phenobarbital induces the activity of SLCO1B1 | [43] | |||
Probenecid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Probenecid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Probenecid inhibits the transporation of ginkolide B by SLCO1B1 | [34] | |||
Affected Drug/Substrate |
Ginkgolide B | Modulation Type | Inhibition | ||
Cell System |
Human enterocyte-like 2 cell (Caco-2) | ||||
Quinine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Quinine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Quinine inhibits the activity of SLCO1B1 | [42] | |||
Tamoxifen |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tamoxifen inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Tamoxifen inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Verapamil |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Verapamil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Verapamil inhibits the transportation of Pitavastatin calcium by SLCO1B1 | [15] | |||
Affected Drug/Substrate |
Pitavastatin calcium | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Vinblastine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Vinblastine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Vinblastine inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Vincristine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Vincristine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Vincristine inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Montelukast |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Montelukast inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 10 microM) | [4] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
Darunavir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Darunavir inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 3.5 microM; Ki = 3.1 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Dehydrocholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dehydrocholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 29.7 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Telaprevir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Telaprevir inhibits the activity of SLCO1B1 (IC50 = 0.0022 microM) | [47] | |||
Boceprevir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Boceprevir inhibits the activity of SLCO1B1 (IC50 = 18 microM) | [48] | |||
Mesalazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Mesalazine inhibits the transportation of Bromsulphthalein by SLCO1B1 | [49] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Caspofungin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Caspofungin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B1 | [50] | |||
Affected Drug/Substrate |
Estradiol 17b-D-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
Linagliptin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Linagliptin inhibits the transportation of Estradiol 17b-D-glucuronide by SLCO1B1 | [13] | |||
Affected Drug/Substrate |
Estradiol 17b-D-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Acarbose |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acarbose inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Acyclovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acyclovir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Allopurinol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Allopurinol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Amantadine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amantadine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Amitriptyline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amitriptyline inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Amodiaquine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amodiaquine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Atenolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atenolol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Atomoxetine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atomoxetine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Benzbromarone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzbromarone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Bestatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bestatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Budesonide |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Budesonide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Bupropion |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bupropion inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Buspirone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Buspirone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Caffeine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Caffeine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Candesartan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Candesartan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Captopril |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Captopril inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Carbamazepine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Carbamazepine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cefadroxil |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cefadroxil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cefamandole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cefamandole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Celecoxib |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Celecoxib inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cerivastatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cerivastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cetirizine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cetirizine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Chloroquine |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chloroquine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Chlorpromazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chlorpromazine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Chlorprothixene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chlorprothixene inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Chlorzoxazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chlorzoxazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Cimetidine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cimetidine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Clarithromycin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Clarithromycin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Colchicine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Colchicine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Desipramine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Desipramine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Dexamethasone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dexamethasone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Dextromethorphan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dextromethorphan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Diazepam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diazepam inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Diclofenac |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diclofenac inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Diethylstilbestrol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diethylstilbestrol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Diltiazem |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diltiazem inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Dipyridamole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dipyridamole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Disopyramide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Disopyramide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Disulfiram |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Disulfiram inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Dofetilide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dofetilide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Doxazosin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Doxazosin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Efavirenz |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Efavirenz inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Eletriptan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Eletriptan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Emtricitabine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Emtricitabine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Enalapril |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Enalapril inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Erlotinib |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Erlotinib inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Erythromycin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Erythromycin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Etoposide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Etoposide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ezetimibe |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ezetimibe inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Felodipine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Felodipine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fentanyl |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fentanyl inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fluconazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fluconazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fluoxetine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fluoxetine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Flutamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Flutamide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fluvastatin |
13 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fluvastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fluvoxamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fluvoxamine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Furosemide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Furosemide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Glipizide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glipizide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Imipramine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Imipramine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Indomethacin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Indomethacin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Isoniazid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Isoniazid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Isradipine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Isradipine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ivermectin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ivermectin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Lamotrigine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lamotrigine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Lansoprazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lansoprazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
L-carnitine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
L-carnitine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Levofloxacin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Levofloxacin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Levothyroxine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Levothyroxine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Lisinopril |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lisinopril inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Loperamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Loperamide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Loratadine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Loratadine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Mephenytoin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Mephenytoin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Metformin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Metformin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Methotrexate |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Methotrexate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Methoxsalen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Methoxsalen inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Metoprolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Metoprolol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Midazolam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Midazolam inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Moclobemide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Moclobemide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nefazodone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nefazodone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nicardipine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nicardipine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nicotine polacrilex |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nicotine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nifedipine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nifedipine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nitrofurantoin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nitrofurantoin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Novobiocin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Novobiocin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Nystatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nystatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Olmesartan medoxomil |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Olmesartan medoxomil inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Omeprazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Omeprazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ondansetron |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ondansetron inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ouabain |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ouabain inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Pantoprazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pantoprazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Paroxetine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Paroxetine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Phenylbutazone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenylbutazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Phenytoin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenytoin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Pilsicainide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pilsicainide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Pindolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pindolol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Pioglitazone |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pioglitazone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Piroxicam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Piroxicam inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Prazosin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Prazosin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Prednisolone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Prednisolone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Procainamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Procainamide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Progesterone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Progesterone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Propranolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Propranolol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Quercetin |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Quercetin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ranolazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ranolazine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Reserpine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Reserpine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Rosuvastatin Calcium |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rosuvastatin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sanguinarine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sanguinarine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sotalol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sotalol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Spironolactone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Spironolactone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sulfaphenazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sulfaphenazole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sulfasalazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sulfasalazine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tenofovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tenofovir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Testosterone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Testosterone inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tetracycline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tetracycline inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Theophylline |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Theophylline inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Thioridazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Thioridazine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Thiotepa |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Thiotepa inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Ticlopidine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ticlopidine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tipranavir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tipranavir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tolbutamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tolbutamide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Topotecan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Topotecan inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Triazolam |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Triazolam inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Trimethoprim |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Trimethoprim inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Valacyclovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valacyclovir inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Valproic Acid |
6 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Varenicline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Varenicline inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Warfarin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Warfarin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Zidovudine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Zidovudine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Simeprevir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Simeprevir inhibits the transportation of Digoxin by SLCO1B1 | [52] | |||
Affected Drug/Substrate |
Digoxin | Modulation Type | Inhibition | ||
Eltrombopag |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Eltrombopag inhibits the transportation of Estrone sulfate by SLCO1B1 | [22] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Prednisone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Prednisone inhibits the transportation of Estrone sulfate by SLCO1B1 | [19] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Belinostat |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Belinostat increases the expression of SLCO1B1 | [54] | |||
Obeticholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Obeticholic acid inhibits the expression of SLCO1B1 | [55] | |||
Acetaminophen |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acetaminophen inhibits the expression of SLCO1B1 | [56] | |||
DT Modulation2 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Bosentan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bosentan inhibits the expression of SLCO1B1 | [57] | |||
Rifampin |
19 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifampin inhibits the activity of SLCO1B1 | [58] | |||
Rifaximin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifaximin inhibits the activity of SLCO1B1 | [59] | |||
Letermovir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Letermovir inhibits the activity of SLCO1B1 | [60] | |||
Amiodarone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amiodarone inhibits the activity of SLCO1B1 | [61] | |||
Elagolix sodium |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Elagolix sodium inhibits the activity of SLCO1B1 | [62] | |||
Glecaprevir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glecaprevir inhibits the activity of SLCO1B1 | [63] | |||
Selexipag |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Selexipag inhibits the activity of SLCO1B1 | [64] | |||
Rifapentine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifapentine inhibits the activity of SLCO1B1 | [65] | |||
Itraconazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Itraconazole inhibits the activity of SLCO1B1 | [66] | |||
Drug in Phase 4 Trial |
|||||
DT Modulation1 |
Silymarin inhibits the activity of SLCO1B1 | [44] | |||
Berberine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Berberine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Drug in Phase 2/3 Trial |
|||||
Silibinin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silibinin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [35] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Silibinin inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 | [36] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
Drug in Phase 3 Trial |
|||||
Benzylpenicillin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzylpenicillin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Glycyrrhizic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycyrrhizin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fusidic Acid |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fusidic Acid inhibits the activity of SLCO1B1 | [73] | |||
Asunaprevir |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Asunaprevir inhibits the activity of SLCO1B1 | [83] | |||
Drug in Phase 2 Trial |
|||||
Genistein |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Genistein inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Genistein inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 | [36] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
PRX-321 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
PRX-321 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [35] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Bisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bisphenol A inhibits the activity of SLCO1B1 | [74] | |||
Drug in Phase 1/2 Trial |
|||||
Sodium taurocholate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sodium taurocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 11.4 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Sodium taurocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Drug in Phase 1 Trial |
|||||
Naringenin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Naringenin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sodium arsenite inhibits the expression of SLCO1B1 | [75] | |||
TAK-875 |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
TAK-875 inhibits the activity of SLCO1B1 | [76] | |||
Licochalcone A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Licochalcone A inhibits the activity of SLCO1B1 | [81] | |||
Luteolin |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Luteolin inhibits the activity of SLCO1B1 | [81] | |||
Drug in Preclinical Test |
|||||
Isoliquiritigenin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Isoliquiritigenin inhibits the activity of SLCO1B1 | [81] | |||
Perfluorododecanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Perfluorododecanoic acid inhibits the expression of SLCO1B1 | [82] | |||
Discontinued Drug |
|||||
MK-571 |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
MK-571 inhibits the transportation of Bromsulphthalein by SLCO1B1 (IC50 = 5 microM) | [4] | |||
Affected Drug/Substrate |
Bromsulphthalein | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
DT Modulation2 |
MK-571 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.3 microM) | [24] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation3 |
MK-571 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Baicalin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Baicalin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Elacridar |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Elacridar inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Valspodar |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valspodar inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Bucladesine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bucladesine induces the activity of SLCO1B1 | [84] | |||
Investigative Drug |
|||||
Bromsulphthalein |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bromsulphthalein inhibits the transportation of Cholyl-glycylamido-fluorescein by SLCO1B1 (IC50 = 0.7 microM; Ki = 0.6 microM) | [6] | |||
Affected Drug/Substrate |
Cholyl-glycylamido-fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Bromsulphthalein inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.08 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
DT Modulation3 |
Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO1B1 (IC50 = 1.7 microM) | [20] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Cell System |
Monkey kidney tissue Fibroblast-like cell lines (COS1)-OATP2B1 | ||||
DT Modulation4 |
Bromsulphthalein inhibits the transportation of Estrone sulfate by SLCO1B1 | [22] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Estrone sulfate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Estrone sulfate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.79 microM) | [26] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
DT Modulation2 |
Estrone sulfate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 0.2 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Lithocholic Acid |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lithocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.7 microM) | [8] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Lithocholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 1.2 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Glycocholic acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycocholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 22 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation2 |
Glycocholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Hyperforin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Hyperforin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (IC50 = 0.82 microM) | [7] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
GW1929 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
GW1929 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 0.3 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
GW-4064 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Gw4064 inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 (Ki = 32.4 microM) | [17] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Aminohippuric acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aminohippuric acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Chelerythrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chelerythrine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Coumarin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Coumarin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Coumestrol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Coumestrol inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Daidzein |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Daidzein inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Glycochenodeoxycholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycochenodeoxycholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Glycodeoxycholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycodeoxycholic acid inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Morin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Morin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Naringin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Naringin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Phalloidin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phalloidin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Sincalide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sincalide inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Taurochenodeoxycholate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Taurochenodeoxycholate inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Tetraethylammonium |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tetraethylammonium inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Clorgyline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Clorgyline increases the expression of SLCO1B1 | [68] | |||
Drug Withdrawn |
|||||
Astemizole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Astemizole inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Fendiline |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Fendiline inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Phenacetin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenacetin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Phenformin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenformin inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Terfenadine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Terfenadine inhibits the transportation of Estradiol-17beta-glucuronide by SLCO1B1 | [14] | |||
Affected Drug/Substrate |
Estradiol-17beta-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Natural Product |
|||||
Cigarette smoke condensate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cigarette smoke condensate inhibits the transportation of Estrone sulfate by by repressing mRNA expression of SLCO1B1 (IC50 = 7.2 microM) | [29] | |||
Affected Drug/Substrate |
Estrone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human hepatoma HepaRG cells-OATP1B1 | ||||
DT Modulation2 |
Cigarette smoke condensate inhibits the activity of SLCO1B1 (IC50 = 7.2 microM) | [31] | |||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Silymarin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silymarin inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 | [36] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
Silybin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silybin A inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 9.7 microM) | [35] | |||
Affected Drug/Substrate |
Estradiol-17-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Silybin B |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silybin B inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 8.5 microM) | [35] | |||
Affected Drug/Substrate |
Estradiol-17-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Silychristin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silychristin inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 9 microM) | [35] | |||
Affected Drug/Substrate |
Estradiol-17-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Allethrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Allethrin inhibits the transportation of Fluorescein by SLCO1B1 (IC50 = 16.5 microM) | [45] | |||
Affected Drug/Substrate |
Fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Tetramethrin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tetramethrin inhibits the transportation of Fluorescein by SLCO1B1 (IC50 = 5.7 microM) | [45] | |||
Affected Drug/Substrate |
Fluorescein | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Silibinin dihemisuccinate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silibinin dihemisuccinate inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 (IC50 = 10 microM) | [4] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Madin Darby canine kidney strain II (MDCKII) cells-OATP1B1 | ||||
Biochanin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Biochanin A inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 (IC50 = 11.3 microM; Ki = 10.2 microM) | [36] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
Epicatechin gallate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
(-)-epicatechin-3-gallate inhibits the activity of SLCO1B1 in a substrate-dependent manner (IC50 = 59 microM) | [46] | |||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Epigallocatechin gallate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
(-)-epigallocatechin-3-gallate inhibits the activity of SLCO1B1 in a substrate-dependent manner (IC50 = 8 microM) | [46] | |||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
DT Modulation1 |
Quercetin inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Quercetin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased uptake of Quercetin | [144] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Silymarin flavolignans |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silymarin flavolignans inhibits the transportation of Estradiol-17-glucuronide by SLCO1B1 | [35] | |||
Affected Drug/Substrate |
Estradiol-17-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293)-OATP1B1 | ||||
Milk thistle |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Milk thistle inhibits the uptake of Estradiol-17-glucuronide by SLCO1B1 (IC50 = 1.3 microM) | [35] | |||
Affected Drug/Substrate |
Estradiol-17-glucuronide | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Breviscapine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Breviscapine inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 28.4 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Herba Epimedii |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Herba Epimedii inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 23.5 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Licorice |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Licorice inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 14.6 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Panax ginseng |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Panax ginseng inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 18.5 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Pomegranat |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pomegranat inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 22.4 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
DT Modulation2 |
Pomegranat inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 28.5 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Pyrola incarnate?Fisch |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pyrola incarnate?Fisch inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 19 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Radix Astragali |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Radix Astragali inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 25.5 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Green tea |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Green tea inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 58.6 microM) | [46] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells | ||||
Flavonoids |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Flavonoids inhibits the transportation of Fluvastatin and rosuvastatin by SLCO1B1 | [51] | |||
Affected Drug/Substrate |
Fluvastatin and rosuvastatin | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Triterpenoids |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Triterpenoids inhibits the transportation of Fluvastatin and rosuvastatin by SLCO1B1 | [51] | |||
Affected Drug/Substrate |
Fluvastatin and rosuvastatin | Modulation Type | Inhibition | ||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Epigallocatechin-4-gallate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Epigallocatechin-4-gallate inhibits the transportation of H-dehydroepiandrosterone sulfate by SLCO1B1 | [36] | |||
Affected Drug/Substrate |
H-dehydroepiandrosterone sulfate | Modulation Type | Inhibition | ||
Cell System |
Human cervical cancer cell line (Hela)-OATP1B1 | ||||
Mix silybin A silybin B |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Mix silybin A silybin B inhibits the activity of SLCO1B1 | [53] | |||
Cell System |
Chinese hamster ovary (CHO) cells-OATP1B1 | ||||
Bilirubin |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bilirubin increases the expression of SLCO1B1 | [67] | |||
Particulate Matter |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Particulate Matter inhibits the activity of SLCO1B1 | [70] | |||
Tobacco Smoke Pollution |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tobacco Smoke Pollution inhibits the expression of SLCO1B1 | [29] | |||
Oroxylin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Oroxylin A inhibits the activity of SLCO1B1 (IC50 = 7.03 microM) | [58] | |||
Cell System |
Human embryonic kidney 293 cells (HEK293)-SLCO1B1 | ||||
Traditional Medicine |
|||||
Jinfukang |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Jinfukang inhibits the expression of SLCO1B1 | [72] | |||
Dietary Constituent |
|||||
Apple juice |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Apple juice inhibits the uptake of estrone sulphate by SLCO1B1 (IC50 = 20.4 microM) | [30] | |||
Affected Drug/Substrate |
Estrone Sulfate | Modulation Type | Inhibition | ||
Cell System |
Human embryonic kidney 293 cells (HEK293) | ||||
Environmental toxicant |
|||||
Polychlorinated dibenzodioxin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Polychlorinated dibenzodioxin inhibits the expression of SLCO1B1 | [29] | |||
Bisphenol F |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bisphenol F inhibits the activity of SLCO1B1 | [74] | |||
Tetrabromobisphenol A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Tetrabromobisphenol A inhibits the activity of SLCO1B1 | [74] | |||
Mycotoxins |
|||||
Aflatoxin B1 |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aflatoxin B1 inhibits the expression of SLCO1B1 | [69] | |||
DT Modulation2 |
Aflatoxin B1 affects the expression of SLCO1B1 protein | [94] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
ochratoxin A |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein affects the uptake of ochratoxin A | [134] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Zearalenone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Zearalenone results in decreased activity of SLCO1B1 protein | [161] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Acute Toxic Substance |
|||||
Okadaic Acid |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Okadaic Acid inhibits the expression of SLCO1B1 | [78] | |||
Kaempferol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Kaempferol inhibits the activity of SLCO1B1 | [81] | |||
Sinensetin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sinensetin inhibits the activity of SLCO1B1 | [81] | |||
Perfluorodecanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Perfluorodecanoic acid increases the expression of SLCO1B1 | [82] | |||
Carcinogen |
|||||
Benzo(a)pyrene |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene inhibits the expression of SLCO1B1 | [79] | |||
Arsenic |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 gene SNP affects the abundance of Arsenic metabolite | [98] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Health and Environmental Toxicant |
|||||
Butyraldehyde |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Butyraldehyde inhibits the expression of SLCO1B1 | [71] | |||
Diethylhexyl Phthalate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diethylhexyl Phthalate inhibits the expression of SLCO1B1 | [77] | |||
Perfluorooctane sulfonic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Perfluorooctane sulfonic acid inhibits the expression of SLCO1B1 | [80] | |||
Endosulfan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Endosulfan co-treated with Tetrachlorodibenzodioxin results in decreased expression of SLCO1B1 mRNA | [119] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Chemical Compound |
|||||
DT Modulation1 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of fluorescein-methotrexate | [116] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Cyclosporine results in decreased activity of SLCO1B1 protein | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Cyclosporine results in decreased expression of SLCO1B1 mRNA | [94] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Lovastatin inhibits the reaction SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Lovastatin results in decreased activity of SLCO1B1 protein | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Ritonavir results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Gemfibrozil inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
SLCO1B1 protein co-treated with ABCC2 protein results in increased transport of Troglitazone analog | [117] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
SLCO1B1 protein results in increased uptake of Lithocholic Acid | [110] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 SNP results in increased abundance of Lithocholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 SNP results in increased abundance of Lithocholic Acid which results in increased susceptibility to Simvastatin | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Bezafibrate inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
SLCO1B1 protein results in increased uptake of Cholic Acid | [110] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 SNP results in increased abundance of Cholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Pravastatin inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Pravastatin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Pravastatin results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Pravastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
SLCO1B1 gene SNP results in decreased transport of Pravastatin | [141] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
SLCO1B1 gene SNP results in increased susceptibility to Pravastatin | [142] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
SLCO1B1 protein mutant form results in decreased transport of Pravastatin | [122] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
SLCO1B1 protein results in increased transport of Pravastatin | [122] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Pravastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Simvastatin inhibits the reaction SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Simvastatin results in decreased activity of SLCO1B1 protein | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 affects the susceptibility to Simvastatin | [149] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
SLCO1B1 gene SNP results in increased susceptibility to Simvastatin | [150] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
SLCO1B1 mutant form affects the susceptibility to Simvastatin | [151] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
SLCO1B1 polymorphism affects the susceptibility to Simvastatin analog | [152] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
SLCO1B1 SNP results in increased abundance of Lithocholic Acid which results in increased susceptibility to Simvastatin | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid which results in increased susceptibility to Simvastatin | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Glyburide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Valsartan results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Ketoconazole results in decreased expression of SLCO1B1 mRNA | [129] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Budesonide inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Budesonide inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Carbamazepine results in increased expression of SLCO1B1 mRNA | [106] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Celecoxib results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Chloroquine affects the localization of SLCO1B1 protein | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Chloroquine inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Chloroquine inhibits the reaction SLCO1B1 protein results in increased import of pitavastatin | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Chloroquine results in increased expression of and results in decreased degradation of SLCO1B1 protein | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Clarithromycin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Diclofenac results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
SLCO1B1 gene polymorphism affects the abundance of Enalapril | [118] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Erythromycin results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Fluoxetine results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
biochanin A results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
hispidulin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
isoliquiritigenin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
kaempferol results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
licochalcone A results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Luteolin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Rifampin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
sinensetin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
SLCO1B1 protein affects the import of Fluvastatin | [125] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
SLCO1B1 protein results in increased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Imipramine results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Levofloxacin results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
SLCO1B1 gene SNP affects the abundance of Methotrexate | [130] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 gene SNP affects the susceptibility to Methotrexate | [131] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 gene SNP results in increased susceptibility to Methotrexate | [132] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Pioglitazone inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Pioglitazone results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Fusidic Acid inhibits the reaction SLCO1B1 protein results in increased uptake of Rosuvastatin Calcium | [126] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Rosuvastatin Calcium | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Rosuvastatin Calcium | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
SLCO1B1 protein results in increased uptake of Rosuvastatin Calcium | [126] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Theophylline results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Ticlopidine results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Valproic Acid results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Valproic Acid results in decreased expression of SLCO1B1 mRNA | [160] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Valproic Acid results in decreased methylation of SLCO1B1 gene | [160] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Valproic Acid results in increased expression of SLCO1B1 mRNA | [54] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased import of Taurocholic Acid | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cerivastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cyanoginosin LR | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to pitavastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Pravastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Rosuvastatin Calcium | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of epyrifenacil metabolite | [120] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [58] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [115] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation13 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation14 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Ursodeoxycholic Acid metabolite | [146] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation15 |
Rifampin results in decreased activity of SLCO1B1 protein | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation16 |
Rifampin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation17 |
Rifampin results in increased expression of SLCO1B1 mRNA | [147] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation18 |
SLCO1B1 protein affects the uptake of Rifampin | [121] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Bilirubin inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
IL1B protein inhibits the reaction Bilirubin results in increased expression of SLCO1B1 mRNA | [67] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Pentanal |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Pentanal inhibits the expression of SLCO1B1 | [71] | |||
DT Modulation1 |
Fusidic Acid inhibits the reaction SLCO1B1 protein results in increased uptake of Rosuvastatin Calcium | [126] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Fusidic Acid results in decreased activity of SLCO1B1 protein | [73] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
TAK-875 inhibits the reaction SLCO1B1 protein results in increased transport of Bile Acids and Salts | [156] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
TAK-875 metabolite results in decreased activity of SLCO1B1 protein | [76] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
TAK-875 results in decreased activity of SLCO1B1 protein | [156] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Dehydroepiandrosterone Sulfate inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Taurocholic Acid inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Luteolin results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Luteolin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2,2',4,4',5,6'-hexabromodiphenyl ether |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
2,2',4,4',5,6'-hexabromodiphenyl ether inhibits the reaction SLCO1B1 results in increased import of estradiol-17 beta-glucuronide | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 results in increased import of 2,2',4,4',5,6'-hexabromodiphenyl ether | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2,2',4,4'-tetrabromodiphenyl ether |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction SLCO1B1 results in increased import of estradiol-17 beta-glucuronide | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 results in increased import of 2,2',4,4'-tetrabromodiphenyl ether | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2',7'-dichlorofluorescein |
6 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
celastrol inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
estrone sulfate affects the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
triptolide affects the reaction SLCO1B1 protein results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
wilforgine inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
wilforine inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [87] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole results in decreased activity of SLCO1B1 protein | [88] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-biphenylamine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
4-biphenylamine inhibits the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-cresol sulfate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
4-cresol sulfate promotes the reaction SLCO1B1 protein results in increased uptake of Taurocholic Acid | [90] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone promotes the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [58] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of SLCO1B1 protein | [58] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased uptake of 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | [58] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
AB-FUBINACA |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
AB-FUBINACA results in decreased activity of SLCO1B1 protein | [91] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
abrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
abrine results in increased expression of SLCO1B1 mRNA | [92] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Aldehydes |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aldehydes results in decreased expression of SLCO1B1 mRNA | [95] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Aminopyrine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aminopyrine results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Apigenin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Apigenin inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Apigenin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
arsenic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased import of arsenic acid | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Atazanavir Sulfate |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bafilomycin A1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bafilomycin A1 inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
belinostat |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
belinostat results in increased expression of SLCO1B1 mRNA | [54] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
benzyloxycarbonylleucyl-leucyl-leucine aldehyde |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SLCO1B1 protein mutant form | [104] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SLCO1B1 protein mutant form which binds to and results in increased uptake of estrone sulfate | [104] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bilirubin ditaurine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bilirubin ditaurine inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Biliverdine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Biliverdine inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
biochanin A |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
biochanin A results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
biochanin A results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol A |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol A inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
bisphenol A results in decreased activity of SLCO1B1 protein | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol F |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol F inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
bisphenol F results in decreased activity of SLCO1B1 protein | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
butyraldehyde |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
butyraldehyde results in decreased expression of SLCO1B1 mRNA | [71] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Cacodylic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 gene SNP results in increased abundance of Cacodylic Acid | [98] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Catechin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Catechin co-treated with Grape Seed Proanthocyanidins results in decreased expression of SLCO1B1 mRNA | [107] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
celastrol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
celastrol inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
cerivastatin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cerivastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cerivastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Chenodeoxycholic Acid |
12 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Chenodeoxycholic Acid results in decreased expression of SLCO1B1 mRNA | [109] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Cisplatin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cisplatin co-treated with jinfukang results in decreased expression of SLCO1B1 mRNA | [72] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Clopidogrel |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Clopidogrel results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Clozapine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Clozapine results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
cyazofamid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
cyazofamid inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [115] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Dehydroepiandrosterone Sulfate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Dehydroepiandrosterone Sulfate inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Dehydroepiandrosterone Sulfate inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Deoxycholic Acid |
12 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
SLCO1B1 protein results in increased uptake of Deoxycholic Acid | [110] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Donepezil |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Donepezil results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dorsomorphin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO1B1 mRNA | [89] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
E 3040 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein co-treated with ABCC2 protein results in increased transport of E 3040 analog | [117] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Enalaprilat |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 gene polymorphism affects the abundance of Enalaprilat | [118] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
epyrifenacil |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of epyrifenacil metabolite | [120] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of epyrifenacil metabolite | [120] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
estrone sulfate |
18 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
4-biphenylamine inhibits the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone promotes the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SLCO1B1 protein mutant form which binds to and results in increased uptake of estrone sulfate | [104] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
bisphenol A inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
bisphenol F inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
cyazofamid inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [115] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
estrone sulfate affects the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [115] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
SLCO1B1 protein affects the uptake of estrone sulfate | [121] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
SLCO1B1 protein binds to and results in increased uptake of estrone sulfate | [104] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
SLCO1B1 protein mutant form results in decreased transport of estrone sulfate | [122] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation13 |
SLCO1B1 protein results in increased transport of estrone sulfate | [122] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation14 |
SLCO1B1 protein results in increased uptake of estrone sulfate | [102] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation15 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation16 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [102] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation17 |
tetrabromobisphenol A inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation18 |
Tobacco Smoke Pollution inhibits the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
fenofibric acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
fenofibric acid inhibits the reaction SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
fexofenadine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein co-treated with ABCC2 protein results in increased uptake of fexofenadine | [123] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of fexofenadine | [124] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
fluorescein-methotrexate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of fluorescein-methotrexate | [116] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of fluorescein-methotrexate | [116] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
gemfibrozil 1-O-acylglucuronide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein co-treated with ABCC2 protein results in increased transport of gemfibrozil 1-O-acylglucuronide | [117] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
glimepiride |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
glimepiride affects the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
glimepiride inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Glutathione |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased import of Glutathione analog | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Glycochenodeoxycholic Acid |
12 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
SLCO1B1 protein results in increased transport of Glycochenodeoxycholic Acid | [127] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Glycocholic Acid |
12 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
SLCO1B1 SNP results in increased abundance of Glycocholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Glycodeoxycholic Acid |
11 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
glycolithocholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein binds to and results in increased transport of glycolithocholic acid analog | [127] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Hematoporphyrins |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Hematoporphyrins inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Hematoporphyrins inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
hispidulin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
hispidulin results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
hispidulin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Hydroxyurea |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased uptake of Hydroxyurea | [128] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
isoliquiritigenin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
isoliquiritigenin results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
isoliquiritigenin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
kaempferol |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
kaempferol inhibits the reaction SLCO1B1 protein results in increased import of Atorvastatin | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
kaempferol inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
kaempferol results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
kaempferol results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
licochalcone A |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
licochalcone A results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
licochalcone A results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Mesalamine |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Budesonide inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Pravastatin inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
SLCO1B1 protein results in increased uptake of Mesalamine | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Monensin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Monensin inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
monomethylarsonic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 gene SNP results in decreased abundance of monomethylarsonic acid | [98] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
naringenin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
naringenin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
naringin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
naringin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Nateglinide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Nateglinide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
nefazodone |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
nefazodone results in decreased expression of SLCO1B1 mRNA | [100] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Nitrogen Dioxide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 gene SNP affects the susceptibility to Air Pollutants results in increased abundance of Nitrogen Dioxide | [133] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
obeticholic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
obeticholic acid results in decreased expression of SLCO1B1 mRNA | [55] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
olmesartan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
olmesartan results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
pentabromodiphenyl ether |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
pentabromodiphenyl ether inhibits the reaction SLCO1B1 results in increased import of estradiol-17 beta-glucuronide | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 results in increased import of pentabromodiphenyl ether | [85] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
pentanal |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
pentanal results in decreased expression of SLCO1B1 mRNA | [71] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorobutanesulfonic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 protein results in increased transport of perfluorobutanesulfonic acid | [135] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorodecanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorodecanoic acid results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorododecanoic acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorododecanoic acid results in decreased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorohexanesulfonic acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorohexanesulfonic acid results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased transport of perfluorohexanesulfonic acid | [135] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorooctanesulfonamide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorooctanesulfonamide analog results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
perfluorooctanesulfonamide results in increased expression of SLCO1B1 mRNA | [137] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorooctane sulfonic acid |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorooctane sulfonic acid results in decreased expression of SLCO1B1 mRNA | [80] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
perfluorooctane sulfonic acid results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased transport of perfluorooctane sulfonic acid | [135] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
perfluorooctanoic acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
perfluorooctanoic acid results in decreased expression of SLCO1B1 mRNA | [80] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
perfluorooctanoic acid results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Phalloidine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Bile Acids and Salts inhibits the reaction SLCO1B1 protein results in increased uptake of Phalloidine | [138] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of Phalloidine | [138] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
phenobarbital quinidine |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
IL1B protein inhibits the reaction phenobarbital quinidine results in increased expression of SLCO1B1 mRNA | [67] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
phenobarbital quinidine results in increased expression of SLCO1B1 mRNA | [67] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
phytochlorin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
phytochlorin inhibits the reaction SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
phytochlorin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
pitavastatin |
8 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Chloroquine inhibits the reaction SLCO1B1 protein results in increased import of pitavastatin | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of and results in increased susceptibility to pitavastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein affects the transport of pitavastatin | [139] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
SLCO1B1 protein results in increased import of pitavastatin | [103] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
SLCO1B1 protein results in increased uptake of and results in increased susceptibility to pitavastatin | [108] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
SLCO1B1 protein results in increased uptake of pitavastatin | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
wilforgine inhibits the reaction SLCO1B1 protein results in increased uptake of pitavastatin | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
wilforine inhibits the reaction SLCO1B1 protein results in increased uptake of pitavastatin | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
PKI 166 |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
PKI 166 inhibits the reaction SLCO1B1 protein affects the transport of estradiol-17 beta-glucuronide | [140] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
PKI 166 results in decreased activity of SLCO1B1 protein | [140] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein affects the transport of PKI 166 metabolite | [140] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Primidone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Primidone results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
propiconazole |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
propiconazole results in decreased expression of SLCO1B1 mRNA | [143] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
propionaldehyde |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
propionaldehyde results in decreased expression of SLCO1B1 mRNA | [71] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
repaglinide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
repaglinide inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 gene SNP affects the metabolism of repaglinide | [145] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
rifamycin SV |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
rifamycin SV inhibits the reaction SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
rifamycin SV results in decreased activity of SLCO1B1 protein | [27] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Rosiglitazone |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rosiglitazone inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Rosiglitazone results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Rutin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rutin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Silicon Dioxide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silicon Dioxide analog results in decreased expression of SLCO1B1 mRNA | [148] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sinensetin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sinensetin results in decreased activity of SLCO1B1 protein | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
sinensetin results in decreased activity of SLCO1B1 protein which results in decreased uptake of Fluvastatin | [81] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
S-Nitrosoglutathione |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
S-Nitrosoglutathione results in decreased expression of SLCO1B1 mRNA | [153] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in decreased expression of SLCO1B1 mRNA | [75] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Stigmasterol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 SNP results in increased abundance of Stigmasterol | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sulfluramid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sulfluramid results in increased expression of SLCO1B1 mRNA | [82] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Sulfobromophthalein |
25 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Apigenin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Budesonide inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Clarithromycin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Cyclosporine inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
glimepiride affects the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [101] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
Hematoporphyrins inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
kaempferol inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
naringenin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
naringin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation10 |
phytochlorin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation11 |
Pravastatin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation12 |
Quercetin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation13 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation14 |
Rutin inhibits the reaction SLCO1B1 protein results in increased import of Sulfobromophthalein | [97] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation15 |
SLCO1B1 protein affects the import of Sulfobromophthalein | [125] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation16 |
SLCO1B1 protein results in increased import of Sulfobromophthalein | [105] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation17 |
SLCO1B1 protein results in increased susceptibility to Sulfobromophthalein | [114] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation18 |
SLCO1B1 protein results in increased uptake of Sulfobromophthalein | [49] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation19 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased import of estrone sulfate | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation20 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [114] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation21 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation22 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased uptake of (5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid | [154] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation23 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased uptake of Atorvastatin | [102] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation24 |
Sulfobromophthalein inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [102] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation25 |
Sulfobromophthalein results in decreased activity of SLCO1B1 protein | [155] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
talinolol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 polymorphism affects the susceptibility to talinolol | [157] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Tartrazine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Taurochenodeoxycholic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 SNP results in increased abundance of Taurochenodeoxycholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Taurocholic Acid |
9 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
4-cresol sulfate promotes the reaction SLCO1B1 protein results in increased uptake of Taurocholic Acid | [90] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Bile Acids and Salts inhibits the reaction SLCO1B1 protein results in increased uptake of Taurocholic Acid | [138] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased import of Taurocholic Acid | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
SLCO1B1 protein binds to and results in increased uptake of Taurocholic Acid | [104] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation5 |
SLCO1B1 protein results in increased import of Taurocholic Acid | [99] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation6 |
SLCO1B1 protein results in increased uptake of Taurocholic Acid | [138] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation7 |
SLCO1B1 SNP results in increased abundance of Taurocholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation8 |
Taurocholic Acid inhibits the reaction SLCO1B1 protein results in increased susceptibility to cyanoginosin LR | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation9 |
Taurocholic Acid inhibits the reaction SLCO1B1 protein results in increased susceptibility to Okadaic Acid | [112] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Taurolithocholic Acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid which results in increased susceptibility to Simvastatin | [111] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
tetrabromobisphenol A |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
tetrabromobisphenol A inhibits the reaction SLCO1B1 protein results in increased uptake of estrone sulfate | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
tetrabromobisphenol A results in decreased activity of SLCO1B1 protein | [74] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Tetrachlorodibenzodioxin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Endosulfan co-treated with Tetrachlorodibenzodioxin results in decreased expression of SLCO1B1 mRNA | [119] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Tetrachlorodibenzodioxin results in decreased expression of SLCO1B1 mRNA | [29] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Ticrynafen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Ticrynafen results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Triclosan |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLCO1B1 mRNA | [93] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Triclosan affects the expression of SLCO1B1 mRNA | [158] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
triptolide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
triptolide affects the reaction SLCO1B1 protein results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
trospium chloride |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
trospium chloride results in decreased activity of SLCO1B1 protein | [159] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Ursodeoxycholic Acid |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Rifampin inhibits the reaction SLCO1B1 protein results in increased uptake of Ursodeoxycholic Acid metabolite | [146] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
SLCO1B1 protein results in increased uptake of Ursodeoxycholic Acid | [110] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
SLCO1B1 protein results in increased uptake of Ursodeoxycholic Acid metabolite | [146] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
verlukast |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
verlukast results in decreased activity of SLCO1B1 protein | [24] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
wilforgine |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
wilforgine inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
wilforgine inhibits the reaction SLCO1B1 protein results in increased uptake of pitavastatin | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
wilforgine results in increased phosphorylation of SLCO1B1 protein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
wilforine |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
wilforine inhibits the reaction SLCO1B1 protein binds to and results in increased uptake of 2',7'-dichlorofluorescein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
wilforine inhibits the reaction SLCO1B1 protein results in increased uptake of pitavastatin | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
wilforine results in increased phosphorylation of SLCO1B1 protein | [86] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
zafirlukast |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
zafirlukast results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
zearalenol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
zearalenol results in decreased activity of SLCO1B1 protein | [161] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
zomepirac |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
zomepirac results in decreased activity of SLCO1B1 protein | [96] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.